Philadelphia Financial Management of San Francisco LLC Purchases New Holdings in ASP Isotopes Inc. $ASPI

Posted by Geri Gentry on Aug 27th, 2026

Philadelphia Financial Management of San Francisco LLC purchased a new position in shares of ASP Isotopes Inc. (NASDAQ:ASPI – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,343,007 shares of the company’s stock, valued at approximately $8,353,504,000. ASP Isotopes accounts for approximately 1.7% of Philadelphia Financial Management of San Francisco LLC’s investment portfolio, making the stock its 19th largest position. Philadelphia Financial Management of San Francisco LLC owned 0.88% of ASP Isotopes as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. HITE Hedge Asset Management LLC bought a new position in ASP Isotopes in the fourth quarter valued at about $2,407,000. Encompass Capital Advisors LLC purchased a new stake in ASP Isotopes in the 1st quarter valued at about $30,551,000. SBI Securities Co. Ltd. raised its holdings in shares of ASP Isotopes by 196.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 152,120 shares of the company’s stock worth $814,000 after purchasing an additional 100,769 shares during the period. AWM Investment Company Inc. bought a new stake in shares of ASP Isotopes during the 2nd quarter valued at $9,837,000. Finally, WIM INVESTMENT MANAGEMENT Ltd bought a new position in ASP Isotopes in the 4th quarter worth about $3,217,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

Insider Activity at ASP Isotopes

In other ASP Isotopes news, Director Todd Wider sold 50,000 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $6.25, for a total value of $312,500.00. Following the completion of the sale, the director owned 722,247 shares of the company’s stock, valued at $4,514,043.75. The trade was a 6.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael Gorley sold 30,000 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $6.27, for a total value of $188,100.00. Following the completion of the transaction, the director directly owned 87,908 shares of the company’s stock, valued at approximately $551,183.16. The trade was a 25.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 279,079 shares of company stock worth $2,049,208 in the last quarter. 14.40% of the stock is owned by corporate insiders.

ASP Isotopes Stock Performance

NASDAQ:ASPI opened at $3.94 on Thursday. The firm’s 50 day moving average is $4.78 and its two-hundred day moving average is $5.27. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. The company has a market cap of $604.04 million, a P/E ratio of -2.98 and a beta of 3.61. ASP Isotopes Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $14.49.

ASP Isotopes (NASDAQ:ASPI – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The business had revenue of $5.12 million for the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Analyst Upgrades and Downgrades

ASPI has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Wall Street Zen upgraded ASP Isotopes from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $13.00.

Check Out Our Latest Analysis on ASP Isotopes

ASP Isotopes Profile

(Free Report)

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.